BioLineRx (BLRX) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to BioLineRx (BLRX) Tops Q3 EPS by 4c

Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q3 Results

November 22, 2016 2:39 PM EST

Roth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.

The analyst commented, We are encouraged by the multiple collaborations initiated between BLRX and biopharma in both clinical and preclinical staged projects, spanning multiple indications.

We believe that BL-8040 remains the lead value driver for BLRX with 1) partial results for the Phase II study of... More